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Inflammation has been known as one of the main keys to the establishment and pro-
gression of cancers. Chronic low-grade inflammation is also a strategic condition that 
underlies the causes and development of metabolic syndrome and obesity. Moreover, 
obesity has been largely related to poor prognosis of tumors by modulating tumor 
microenvironment with secretion of several inflammatory mediators by tumor-associated 
adipocytes (TAAs), which can modulate and recruit tumor-associated macrophages. 
Thus, the understanding of cellular and molecular mechanisms that underlay and link 
inflammation, obesity, and cancer is crucial to identify potential targets that interfere 
with this important route. Knowledge about the exact role of each component of the 
tumor microenvironment is not yet fully understood, but the new insights in literature 
highlight the essential role of adipocytes and macrophages interplay as key factor to 
determine the fate of cancer progression. In this review article, we focus on the functions 
of adipocytes and macrophages orchestrating cellular and molecular mechanisms that 
lead to inflammatory modulation in tumor microenvironment, which will be crucial to 
cancer establishment. We also emphasized the mechanisms by which the tumor pro-
motes itself by recruiting and polarizing macrophages, discussing the role of adipocytes 
in this process. In addition, we discuss here the newest possible anticancer therapeutic 
treatments aiming to retard the development of the tumor based on what is known about 
cancer, adipocyte, and macrophage polarization.
Keywords: adipocytes, cancer, tumor microenvironment, obesity, inflammation, tumor-associated macrophages, 
tumor-associated adipocytes, macrophage polarization
iNTRODUCTiON
The Tumor Microenvironment
Tumor is not composed only of the cancer cells. Instead, there is a dynamic and mutualist rela-
tionship between tumor cells and the surrounding stroma (1). Studies have shown an intimate 
relationship between tumor mass cells and their extracellular matrix correlating this interaction 
with cancer establishment, progression, and metastasis. The extracellular matrix is responsible not 
only for the structural support of the cells but also for storing important signaling molecules, such 
as chemokines (2).
TAble 1 | Cellular composition of the tumor microenvironment and the implication of the cytokines secretion in the tumor development.
Cell type Cytokines Function
Classical macrophages (M1) IL-1β, IL-12, TNF-α Proinflammatory M1 profile. It makes the environment prone to inflammation and tumor cells 
elimination can be triggered by secretion of IL-1β, IL-12, and TNF-α cytokines
Alternative macrophages (M2) IL-4, IL-10, TGF-β Anti-inflammatory M2 profile. It maintains the tumor by cytokines secretion involved in tissue 
regeneration and remodeling, such as TGF-β, IL-10, IL-4, increasing the tumor cells viability, 
facilitating tissue invasion by tumor cells, and metastasis
Adipose cells IL-6, IL-10, IL-13, IL-33, TGF-β, 
TNF-α
Adipose tissue can favor tumor growth and development by producing anti- and 
proinflammatory mediators in a deregulated manner. Proinflammatory cytokines, such as 
IL-6 and TNF-α, are secreted, promoting cell proliferation and angiogenesis. Other cytokines, 
such as IL-13, IL-10, and TGF-β are also produced and their role is to maintain the tumor, 
regenerating tissues, and inhibit anticancer immune cells recruitment
CD8+ T cells IFN-γ CD8+ T secrete large amounts of cytotoxic granules and IFN-γ, which polarizes macrophages 
into the proinflammatory M1 profile and inhibits Treg lymphocytes
CD4+ T and Treg cells IL-10, TGF-β These cells can assist in the suppression of other immune cells: IL-10 and TGF-β secretion 
inhibits antitumor NK and CD8+ T cells
Neutrophils TGF-β, TNF-α, IL-4, IL-6, IL-1β Neutrophils have both pro- and antitumor functions. They help to maintain the M2 profile by 
producing IL-4 and TGF-β, which support the tumor cells growth. These cells can also play an 
anticancer role, secreting TNF-α, IL-6 and IL-1β to prolong the CD8+ T population
2
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Cancer cells recruit non-malignant cells into their micro-
environment, where reciprocal modulation takes place: tumor 
cells configure several cell types and change their metabolism to 
favor tumor promotion, resulting in a more anti-inflammatory 
environment and the avoidance of antitumor immune cells. Each 
non-malignant cell type exerts a function in the microenviron-
ment in order to support tumor growth and development, which 
leads to metastasis (3).
An important component recruited for the tumor stroma is 
the tumor-associated macrophage (TAM). These cells have an 
extremely important action for tumor progression (4). Mac-
rophages are recruited and polarized to the M2 configuration in 
which they act to compose the tumor microenvironment mediat-
ing an immunosuppression phenome. TAMs are chemoattracted 
to the microenvironment mainly by chemokines such as CCL2, 
which are produced in high quantities by malignant cells (5). In 
the tumor site of action, TAMs produce cytokines such as IL-10, 
IL-4, and IL-13 that will act to repair tissues and attract other 
auxiliary cells that can activate TAM and hence, promoting tumor 
growth (6).
Similarly, neutrophils are also part of the tumor microenvi-
ronment, being an important source of cytokines and reactive 
oxygen species (ROS). T cells are also found acting in an immu-
nosuppressive manner, secreting TGF-β and IL-10 that inhibit 
the antitumor activity of cytotoxic T-cells and natural killer cells 
(2). Fibroblasts associated with the tumor have a fundamental 
participation in the production of vascular endothelial growth 
factor (VEGF), that induces angiogenesis, along with vascular 
endothelial cells that are responsible for forming blood vessels 
that support tumor growth and metastasis (1).
In addition to immunological cells, the tumor microenviron-
ment is composed of adipose tissue. Adipose tissue has been 
widely studied and it has a great potential as an endocrine organ 
(7), since this tissue is known to be able to secrete a huge variety 
of different adipokines, such as leptin, hepatocyte growth fac-
tor, and adiponectin. Adipocytes can stimulate the growth and 
the survival of tumor cells (8) and then are able to perform a 
crosstalk with the surrounding cells, releasing fatty acids that can 
be metabolized by tumor cells and used as energy source.
Tumor-associated adipocytes (TAAs) assist in the recruitment 
of macrophages to the microenvironment and their polariza-
tion to the alternative M2 configuration via CCL2, IL-1β, and 
CXCL12 (9). Recently, Nishimoto et al. showed that macrophage 
accumulation in the microenvironment is due to not only the 
secretion of CCL2 by adipocytes but also the release of degenerate 
adipocyte DNA (10).
The complex cellular arrangement that constitutes the 
tumor microenvironment is dynamic. Malignant cells are 
dependent on the cells of the immune system and fat cells to 
maintain and develop. Therefore, including all factors, the tumor 
microenvironment possesses the proliferative abilities to evade 
suppression, resist cell death, develop replicative immortality, 
induce angiogenesis, and stimulate not only invasion but also 
metastasis. A variety of cells and cytokines can be found in tumor 
microenvironment and they have different implications in cancer 
progression (Table 1).
Tumor-Associated Adipocytes
Cancer cells usually activate wound-healing response of the 
host to generate a supportive microenvironment to favor tumor 
development (4). It has been described that cancer progression is 
promoted by stromal cells, such as cancer-associated fibroblasts 
(CAFs) or TAMs, which secrete extracellular matrix components, 
chemokines, and growth factors that stimulates cell migration 
and metastasis (2). The contribution of fibroblasts, endothelial, 
and inflammatory cells to cancer establishment has been exten-
sively studied (1). However, the comprehension of the real role 
of adipocytes in cancer environment is still poorly understood 
since adipocytes were mainly considered an energy storage depot 
until recently. Only recently, adipocytes started to be beheld as 
endocrine and inflammatory cells producing hormones, growth 
factors, cytokines, and other molecules such as adipokines (5). 
Moreover, early local tumor invasion results in immediate prox-
imity of cancer cells to adipocytes in breast cancers (3). Hence, 
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adipocytes represent extraordinary candidates to regulate tumor 
behavior through heterotypic signaling processes.
The interaction of adipose tissue with tumor cells is widely 
described and characterized as poor prognosis. Adipose tissue is a 
very dynamic and complex tissue, mostly composed of adipocytes 
but it also contains macrophages, lymphocytes, endothelial cells, 
pericytes, and adipocyte progenitor cells. Cancer development 
and progression is improved by both adipocytes and stromal 
vascular cells in adipose tissue (11). The enhance of the adipose 
tissue, leading to a series of metabolic deregulations, is a key 
characteristic of obesity and a greater risk of cancer (12). It is 
known that inflammation is closely linked to obesity. Likewise, 
obesity is intimately related to cancer evolution. Thus, obesity, 
inflammation, and tumor comprise an important triangle that 
can orchestrate a critical modulation in tumor microenviron-
ment through the action of its mainly players: adipocytes and 
macrophages.
Adipocytes produce inflammatory cytokines, such as TNF-α, 
IL-6, IL-1β, and CCL2 (9, 13), which leads to directly inflammatory 
cell (e.g., lymphocytes and macrophages) recruitment, infiltration 
and accumulation in adipose tissue, and establishes a state of low 
grade chronic inflammation (14, 15). Macrophage infiltration was 
reduced in CCL2 knockout mice, or its receptor CCR2, as well 
as the obesity-induced inflammation in visceral adipose tissue 
(16, 17). Visceral adipose tissue from obese people are frequently 
associated with increased levels of CCL2, TNF-α, IL-1, IL-6, and 
inducible nitric oxide synthase (iNOS) (18). In subcutaneous 
fat pads, both macrophage recruitment and expression of CCL2 
were elevated when mice was ovariectomized, suggesting that 
increase inflammation in postmenopausal breast tissue may be 
due to CCL2 (18). Moreover, the amount of CCL2 produced is 
increased due to recognition of cell-free DNA (cfDNA) from 
degenerate adipocytes. Obese mice showed an increase in cfDNA 
release leading to a higher accumulation of macrophages, which 
aggravates inflammation (10). In response to CCL2 and IL-1β, 
recruited macrophages secrete CXCL12 in order to induce angio-
genesis and support the expanding tissue (9).
Reactive oxygen species are also involved in the tumorigenic 
process. When a state of chronic inflammation is established in 
adipose tissue, the generation of ROS is observed (19). In low 
concentrations, ROS has mitogenic properties and can be con-
sidered as a tumor promoter (20).
Comparing adipose tissue macrophages (ATMs) and mono-
cyte-derived macrophages (MDMs) from the same obese patients, 
ATM secreted soluble factors that induce inflammation and lipid 
accumulation in cancer cells (T47D and HT-29), but MDM did 
not. Additionally, functional clusters, such as cytokine–cytokine 
receptor interaction (particularly CXC chemokine) signaling, 
and cancer-related pathways are overexpressed only in ATM. 
Gene expression profiles of TAMs were more similar to ATM 
than MDM. Interestingly, MDM also acquired an ATM pheno-
type and modulated the secretion of factors by preadipocytes but 
not by mature adipocytes (21).
White adipose tissue from obese individuals present abundant 
crown-like structures (CLSs) which are constituted by infiltrating 
macrophages surrounding dead adipocytes. Enhanced rates of 
CLS in white adipose tissue are often associated with increased 
production of the inflammatory mediators in obese individuals. 
Macrophages from CLS trigger adipocyte cell death, aggravating 
the tissue inflammatory condition and attracting more infiltrated 
macrophages to the tumor microenvironment (22). Additionally, 
obese adipose cells produce the nuclear protein high mobility 
group box 1 in large quantities (23), a danger signal that attracts 
and activates immune cells (24).
The initial factors that trigger chronic inflammation of adipose 
tissue in obesity are unclear. Evidence suggests it might be medi-
ated by hypoxia, necrosis, increased secretion of immunomodu-
latory factors (such as cytokines, chemokines, hormones, and 
growth factor), lipolysis, and free-fatty acids release (25).
Tumor-associated adipocytes can be delipidated, shedding 
elements of adipose tissue into tumor microenvironment. Those 
adipocyte-derived elements can be used by cancer cells to 
promote tumor growth. TAA can potentially dedifferentiate 
into fibroblast-like cells. Free-fatty acids released by adipocytes 
can be used by cancer cells to fuel its growth and proliferation. 
In addition, free-fatty acids can activate and modulate other cells 
such as myocytes, macrophages, and vascular endothelial cells 
favoring the formation of protumorigenic microenvironment 
(4, 26). Likewise, CAFs, in conjunction with others stromal 
cells, promote tumor progression (27). Obese adipose tissue 
can regulate tumor development in different ways, either by 
providing energy via free-fatty acids or through adipokines, 
cytokines, or miRNAS. An increasing number of miRNAs has 
been associated with several diseases, such as cancer, diabetes, 
and obesity. Recently, Thomou et al. (28) which shows the abil-
ity of adipose tissue to regulate gene expression in other tissues 
through circulating exosomes containing miRNAs showing the 
enormous influence that adipose tissue can exerts on other tissues 
by directly silencing genes.
Malignant cells around adipose tissue secrete sufficient 
amounts of cytokines that will polarize macrophages to the M2 
alternative profile, promoting the establishment of an environ-
ment more conducive to the development of a tumor (6). 
Macrophages tend to switch from an initial M1 profile to a later 
M2 profile (29). In obese mammary adipose tissue, macrophages 
showed a decreased IL-10 expression and increased iNOS and 
CD11c expression consistent with a M1 polarization phenotype, 
on the other hand, the cells showed an increase of CD206 expres-
sion, suggesting a mixed polarization phenotype in obese mam-
mary glands (9). The coculture of adipocytes with macrophages 
(THP-1-derived cells) induces a shift of THP-1 macrophages to a 
M2 phenotype (30). Since in this experiment there was no contact 
between the cell types, the findings suggest that the crosstalk is 
mediated by soluble factors secreted by adipocytes promoting 
macrophage polarization.
Tumor-Associated Macrophages
The macrophages polarization occurs through different ligands 
that act modulating their metabolism. This macrophage plastic-
ity is essential for the establishment of an antitumor immune 
system functionality. These cells can vary from a configuration 
that inhibit tumor growth and induce cell death (the classical 
M1 profile) to a configuration that stimulates cancer progression 
and tissue repair (the alternative M2 profile) (31).
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Cancer development and progression are deeply regulated 
by immune system. It is known that the immune cells infiltra-
tion at the tumor site may affect the progression of malignancy 
and metastasis (32), where macrophages are the most abundant 
immune cells in the tumor microenvironment (33). Macrophages 
are characterized by their plasticity, flexibility and ability to 
integrate distinct signals from the microenvironment acquiring 
distinct phenotypes (34). In this context, macrophages can be 
divided into two subtypes: M1 macrophages, characterized as 
promoting Th1 response and strong microbicidal and tumoricidal 
activity; and M2 macrophages that promote Th2 response, tissue 
remodeling, immune tolerance, and tumor progression (35, 36).
Activated macrophage population phenotype can change 
occasionally. In obesity, for instance, there is a macrophage 
phenotype switch from M2 to M1 (37). Contrarily, tumor pro-
gression is often associated with macrophage phenotype changes 
from classically activated (M1) to alternatively activated (M2) (6). 
Macrophage plasticity occur in consequence of a dedifferentiation 
of the original cells back to their resting state or the migration of 
a new population of macrophages into the tissue site to replace 
the original cells. Other studies have indicated that changes in cell 
stimuli directly impact the macrophage polarization (M1 or M2) 
(38). Then, macrophages are capable of repolarizing in response 
to modifications in the local microenvironment, permitting them 
to shape the local inflammatory milieu to adjust to different 
sources of stimuli.
M1 macrophages are stimulated by microbial products or 
proinflammatory cytokines (IFN-γ and TNF-α) (34). M1 mac-
rophages are known sources of proinflammatory cytokines such 
as TNF-α, IL-1, IL-6, IL-12, and type I IFN; chemokines such as 
CXCL1–3, CXCL-5, and CXCL8–10; and high antigen presenta-
tion function, nitric oxide, and ROS generation (39). Classically 
activated macrophages are deeply involved in the recognition and 
destruction of cancer cells. After recognition by M1 macrophages, 
tumor cells can be killed through several mechanisms, which 
include contact-dependent phagocytosis and cytotoxicity (40).
M2 macrophages are anti-inflammatory cells which aid in 
the process of angiogenesis and tissue repair. These cells are 
characterized by the upregulation of Dectin-1, mannose recep-
tor, scavenger receptors, CD163, CCR2, CXCR1, and CXCR2, in 
addition to the production of large quantities of IL-10 and other 
anti-inflammatory cytokines (35, 41). The expression of IL-10 
by M2 macrophages promotes a Th2 response, and Th2 cells, in 
turn, upregulate the production of IL-3 and IL-4. Furthermore, 
M2 macrophages are not capable of efficient antigen presentation 
(42, 43). M2 macrophages have different subsets, each induced 
by a different set of molecules and different activation responses. 
For this, M2 macrophages can be further divided into subgroups 
called M2a, M2b, M2c, and M2d. M2a macrophages are induced 
by the Th2cytokines, IL4 and IL13; their function is to activate 
Th2 response by producing IL-10, TGF-β, and IL-1ra, with the 
purpose of promoting type II inflammation to kill parasites. 
M2b cells are induced by immune complexes, lipopolysaccha-
rides, IL-1R and TLRs ligands; they produce cytokines such as 
IL-1, IL-6, TNF-α, and IL-10, acting in the metastasis control, 
suppressing tumor growth and inducing a Th1 response. IL-10, 
TGF-β, and glucocorticoids can induce macrophages to 
differentiate to M2c phenotype, which is involved in immune 
suppression, tissue repair, and matrix remodeling (34, 44). Recent 
research has demonstrated that TAMs exhibit functions like those 
of M2 macrophages and can be classified as M2d subtype. M2d 
or TAMs exhibit functions that may help tumor progression by 
allowing the growth of new blood vessels growth, which feeds 
the malignant mass of cells, further promoting their growth (45).
The most important characteristic of TAM is the ability to 
promote the establishment and progression of cancer. This 
promotion occurs through secretion of cytokines that can act 
directly on tumor cells or indirectly, by recruiting auxiliary cells. 
The alternative M2 configuration is the most abundant cell type 
present in the tumor microenvironment being directly related to 
inhibition of proinflammatory cell recruitment and inhibition of 
polarization to the classic M1 type (46).
Tumor cells produce cytokines responsible for the recruitment 
and polarization of macrophages to M2 profile such as IL-4, 
IL-10, IL-13, and TGF-β, as well as chemokines such as CCL2 
(MCP-1), CCL3, and CCL14. When infiltrated, macrophages 
increase the expression of mannose and galactose receptors as 
well as the production of VEGF, cyclooxygenase-2 (COX-2)-
derived prostaglandin E2 (PGE2), and IL-10, thus rendering the 
microenvironment against inflammation and favorable to tumor 
development (47). Moreover, TAM phenotype expresses Arg1 
and TGF-β in order to recruit Th2 lymphocytes to the tumor site 
leading to an increase in IL-4 production and maintenance of the 
M2 population (7).
Tumor-associated macrophage cells have an immunosuppres-
sive role inhibiting the antitumor response of T cells. At the site 
of the tumor, the high production of IL-10 derived from TAMs 
indirectly inhibits T cell activation by down regulating IL-12 pro-
duction by dendritic cells, which, in turn, prevents the TCD8+ 
response. Furthermore, IL-10 and TGF-β production by TAM 
promotes induction of regulatory T cells that are installed locally 
and make the environment even more immunosuppressed (48).
Studies have shown that TAMs do more than rendering an 
anti-inflammatory microenvironment. TAMs are also related 
to cancer promotion, angiogenesis induction, as well as tumor 
cell migration and metastasis (45). Angiogenesis is the first step 
involved in the occurrence of metastasis. In addition to nour-
ishing tumor mass, TAMs are present throughout the process. 
TAMs can reorganize the extracellular matrix. Among the list 
of proangiogenic growth factors secreted by TAMs, the follow-
ing factors can be highlighted: epidermal growth factor, VEGF, 
platelet-derived growth factor, migration inhibitory factor, 
TNF-α, TGF-β, IL-8, and IL-1β, thymidine phosphorylase, and 
the chemokines CCL2 and CXCL8 (49). These factors can induce 
the formation of a network in which tumor cells can benefit by 
receiving nutrients and migrating to other sites.
Monocytes/macrophages recruitment into tumor microen-
vironment is mainly controlled by cytokines, chemokines and 
growth factors produced by stromal and malignant cells (45) 
(Figure 1). Many cancers like breast (50), prostate (51), ovarian 
(52), and non-small lung cancers (53), use the release of CCL2 
for recruitment and polarization of M2 macrophages (54). Others 
chemokines such as CXCL12, CXCL8, CXCL1, CXCL13, CCL4, 
CCL5 (55), CCL17, and CCL22 (56), have been identified in 
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FigURe 1 | Cross-talk between adipocytes, macrophages, and cancer cells modulating the tumor microenvironment. In the protumorigenic state, macrophages  
are attracted to the tumor site via chemokines, such as CCL-2, -4, and -5 produced by malignant cells, resident macrophages, and inflamed adipose tissue. Obese 
adipose tissue can favor tumor growth and development by producing anti- and proinflammatory mediators in a deregulated way. Proinflammatory cytokines, such 
as IL-6 and TNF-α, are secreted by adipose cells acting on the tumor modulating the Janus kinase/STAT pathway promoting cell proliferation and angiogenesis. 
Anti-inflammatory cytokines, such as IL-13, IL-10, and TGF-β are also produced by this tissue and maintain the tumor, regenerating tissues, and inhibiting the 
recruitment of immune anticancer cells. In addition, inflamed adipocytes produce leptin in large amounts, which act on epithelial cells leading to neovascularization, 
thus increasing tumor invasion. Degenerate adipose cells attract M1 macrophages that can form a crown-like structure around the inflamed adipose cell to eliminate 
them. This elimination can lead to FFA release that will nourish the tumor giving energetic support to the malignant cells. In addition, degenerate adipose cells 
release cfDNA that are recognized by macrophage TLR9 receptors, thus increasing the production of CCL2 in these cells, leading to increased recruitment of 
monocytes. Macrophages are attracted to the tumor microenvironment and polarized to the M2 alternative profile. Tumor cells produce IL-4, IL-10, and IL-6; 
adipose cells produce IL-13, IL-10, and TGF-β; and neutrophils IL-4 and TGF-β polarizing and maintaining the macrophages in the M2 configuration. More 
macrophages are attracted into the microenvironment via CCL2, and help to maintain the tumor by producing cytokines that act on tissue regeneration, such as 
TGF-β, IL-10, IL-4, and arginase-1, increasing the viability of the tumor cells, leading to invasion and metastasis. The M2 configuration regulates the recruitment of 
immune cells, inhibiting the recruitment of CD8+ T and NK cells via TGF-β in addition to maintaining Treg cells by IL-4 production along with production of IL-33 
produced by adipocytes. Treg cells act by maintaining the M2 configuration producing IL-10 and TGF-β which also activated CD4+ T activation. CD4+ T cells assist 
in the inhibition of anticancer cells through IL-10 and TGF-β secretion inactivating NK cells and CD8+ T cells. Neutrophils are also found in the tumor 
microenvironment. Cancer cells produce CXCL2 in large numbers, recruiting neutrophils that help maintain the M2 profile by producing IL-4 and TGF-β, which also 
help the growth of tumor cells. Tumor-associated neutrophils are responsible for increasing the mutagenic level of cells by the production of reactive oxygen species 
(ROS), which cause damage to the DNA of cells, in addition to M2 macrophages, to produce VEGF, and increasing angiogenesis. Neutrophils in blood vessels may 
form structures such as NETs that help malignant cells stabilize in place and enter the metastatic phase. In the antitumorigenic state, normal adipose cells secrete 
leptin which, together with MHCII, have acted in the recruitment of CD8+ T cells. CD8+ T secrete large amounts of IFN-γ polarizing macrophages into the 
proinflammatory M1 profile and inhibit Treg cells. M1-like cells act on the secretion of cytokines that have the function of making the surroundings more and more 
inflamed and destroy tumor cells, such as IL-1β, IL-12, and TNF-α, and recruit more macrophages to the site via CCL2. Tumor cells, when destroyed, release 
DAMPs, which recruiting more macrophages and neutrophils into the site, which aid in inflammation secreting nitric oxide (NO) and causing severe damage to cells. 
Abbreviations: IFN-γ, interferon γ; IL, interleukin; MHCII, class II major histocompatibility complex; TNF-α, tumor necrosis factor α; TGF-β, transforming growth factor 
β; CCL2, 4 and 5, chemokine (C-C motif) ligand 2, 4, and 5; CXCL2, chemokine (C-X-C motif); VEGF, vascular endothelial growth factor; NK, natural killer; T-reg, 
regulatory T cell; CD8 and CD4, cluster of differentiation 8 and 4; cfDNA, cell-free DNA; FFA, free-fatty acid.
6Corrêa et al. Adipocytes and Macrophages in Cancer
Frontiers in Immunology | www.frontiersin.org September 2017 | Volume 8 | Article 1129
neoplastic tissues as tumor cells products. Moreover, growth fac-
tors can be released by tumor cells, like VEGF, placental growth 
factor, and macrophage-colony stimulating factor (M-CSF). These 
have also been described as promoters of monocyte/macrophage 
recruitment (57, 58).
Tumor microenvironmental factors, such as leukemia inhib-
itory factor, IL-6, and M-CSF, were shown to promote TAM gen-
eration. IL-6 can activate the signal transducer and the activator 
of transcription 3 (STAT3), which is a signal transduction mol-
ecule that converges to many oncogenic signaling pathways, and 
controls the M2-polarization of macrophages as well (59). STAT3 
is a constitutive activator in tumor cells (60) and is involved in the 
initiation and progression of epithelial ovarian carcinoma (61). 
IL-6/STAT3 pathway further regulates M2 macrophage polariza-
tion and promotes tumorigenesis (62).
Macrophage polarization in the tumor inflammatory micro-
environment can be regulated by COX-2 and its downstream 
arachidonic acid metabolite product, PGE2 (63). IL-6 can mediate 
COX-2 expression in a variety of tumors, including colorectal 
cancer (CRC) (64), breast cancer (65), melanoma (66) and 
prostate cancer (67); additionally, it induces PGE2 production 
in mesenchymal stem cells, lung cancer, and cervical carcinoma 
(68, 69). Both molecules contribute to carcinogenesis by stimu-
lating cancer cell proliferation, inhibiting apoptosis, increasing 
invasiveness, and modulating inflammation and immunity 
through the induced release of Th2 cytokines, such as IL-10, 
TGF-β, IL-4, and IL-13, by TAMs and the tumor cells (70).
Analysis of the molecular basis of the TAM phenotype has 
identified the transcriptional factors NF-kB and hypoxia induc-
ible factor 1 (HIF-1) as central regulators of tumor progression 
and metastasis (71). NF-kB activation is crucial for cancer-related 
inflammation and is associated with M1 macrophages during the 
early phase of tumorigenesis. However, at the late phase of tumo-
rigenesis, macrophages are reprogramed to TAMs or M2-like 
macrophages presenting low NF-kB activation but increased 
immunosuppressive capacity (72). Hypoxia executes its effect on 
macrophages through two isoforms of HIF, HIF-1a, and HIF2 
(73). It was demonstrated that high lactic acid produced by 
tumor cells in this hypoxic environment has a critical function in 
signaling; specifically, it induces the expression of VEGF and pro-
duces hypoxia-inducible factor-1α (HIF-1α) and HIF-2α, which 
regulate the transcription of genes associated with angiogenesis. 
Moreover, recent studies also showed tumor hypoxia enhances 
non-small cell lung cancer metastasis by promoting macrophage 
M2 polarization through the activation of ERK signaling (29, 74).
Numerous miRNAs have been shown to be highly expressed 
in polarized macrophages, particularly, miRNA-155, miRNA-
125, and miRNA-378 for M1 polarization also as miRNA-let-7c, 
miRNA-9, miRNA-21, miRNA-146, miRNA147, and miRNA-187 
for M2 polarization (75, 76). New studies demonstrated a novel 
miR-155-mediated mechanism for promoting the M1 phenotype 
of macrophage polarization. Because miR-155-modified TAMs 
can regain tumor-killing capacity, this study provides a potential 
therapeutic approach in cancer treatment (77).
Malignant fibrous histiocytoma amplified sequence 1 
(MFHAS1) is a predicted oncoprotein that demonstrates tumo-
rigenic activity in vivo (78). In recent studies, it was detected a 
positive association between MFHAS1 expression in TAMs 
and human CRC, where CRC cells induced M2 polarization of 
TAMs through MFHAS1 induction and subsequent STAT6 and 
KLF4 activation to promote CRC progress. Therefore, the role of 
MFHAS1 is a regulator of macrophages polarization and CRC 
development (79).
Macrophages may play an important role in a process called 
epithelial–mesenchymal transition (EMT). Studies demonstrated 
that M2-polarized TAMs promoted EMT in pancreatic cancer 
cells, suggesting a novel mechanism by which M2-polarized 
TAMs may contribute to the aggressive behavior of pancreatic 
cancer cells by TLR4/IL-10 signaling (80).
Modulation of Cancer Microenvironment 
As Pharmacological Therapy Target
Many factors can contribute to tumorigenesis, tumor progression, 
and metastasis. Amongst these, the tumor microenvironment is 
crucial when determining cellular behavior and secretion pat-
tern. Macrophages present in the tumor microenvironment can 
display different phenotypes as a product of the cytokines they are 
exposed to. TAMs represent a prevalent hybrid population within 
tumor microenvironment which usually exhibit an M2-like phe-
notype (81). The tumor microenvironment and its components, 
TAMs and their M2-polarized characteristics included, have been 
extensively studied as therapeutic targets both in conventional 
treatments and innovative ones.
Morphine is a traditional opioid drug used in clinical practice 
for pain management of cancer patients. However, it has been 
discussed whether its effects boost or hinder tumor growth and 
metastatic behavior (82). Khabbazi et al. developed an approach to 
enlighten the role morphine treatment might play on the modula-
tion of the tumor microenvironment. Macrophages RAW264.7 
and bone marrow derived were polarized either using IL-4 or 
4T1 breast cancer cells, as a paracrine communication, toward 
the M2 profile. Thus, there was a significant escalation in MMP-9 
expression, which can uphold invasiveness and angiogenesis. 
Morphine was shown to prevent said increase, and, therefore, it 
was hypothesized that the drug might be able to inhibit matrix 
degradation in the tumor microenvironment. The opioid also 
lowered arginase-1 expression, which can also be beneficial since 
its activity boosts breast cancer cell proliferation (83, 84).
Along with new found mechanisms for commonly used drugs, 
intravenous immunoglobulin (IVIg) is a treatment licensed for 
a variety of chronic autoimmune diseases such as Kawasaki’s 
disease and Idiopathic thrombocytopenia purpura, and used 
“off-label” for a number of other conditions (85). Studies show 
that IVIg can either have anti-inflammatory action (as expected 
in clinical practice) on M1 macrophages, or induce phenotype 
shift from M2 to M1. The drug can elicit either pro- or anti-
inflammatory reactions, conditional to the state of macrophage 
polarization. It has been demonstrated that IVIg significantly 
hindered secretion of TNF-α, IL-12p40, and CCL2 after M1 
macrophages were stimulated with LPS without, nonetheless, 
affecting their property to inhibit tumor growth. Curiously, when 
M2 macrophages received the same treatment, the expression of 
TNF-α, IL-12p40 was boosted. IVIg is now considered to be an 
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immunomodulatory agent, whose effects vary according to the 
status of the macrophages treated. Such modulatory properties 
can be extremely valuable in cancer treatments, for it has been 
demonstrated that IVIg halted tumor progression and metastasis 
in a model of tumor-associated myeloid cells (86). Another new 
discovery about an old ally is the evidence that administration 
of moderate doses of dopamine challenges tumor growth and 
contributes to vascular stabilization in a rat C6 glioma model. 
This new property found by Qin et al. can influence TAMs with 
M2 profile toward the M1 phenotype. Dopamine boosts vascular 
normalization in tumors by reprogramming M2 macrophages 
partly via dopamine receptor 2 and partly via downregulation of 
the VEGF/VEGFR2 pathway (87).
Moreover, regarding the immunomodulatory properties of 
substances which can promote polarization of macrophages, 
the research of Shiri and collaborators can also be highlighted. 
Their study used curcumin, a fat-soluble substance extracted 
from Curcuma longa, which was bioengineered to enhance its 
bio availabitity into DNC-dendrossomal curcumin (88). The 
DNC formulation has promoted beneficial effects on a murine 
metastatic breast cancer model, providing an enhanced popula-
tion of M1 macrophages in detriment of the M2 population (89).
Approved treatments are different in every country, depend-
ing on their culture and technological development. For instance, 
cantharidin is one active ingredient of blister beetles, which is used 
traditionally in China for cancer treatment (90). Due to toxicity, 
a demethylated molecule was engineered, the norcantharidin 
(NCTD), which is routinely used against hepatoma, colorectal 
carcinoma and breast cancer (91, 92). An interesting new found 
feature regarding NCTD is its ability to suppress tumor growth 
through conversion of M2 polarized macrophages to M1 phe-
notype in a model of murine hepatoma. TAMs extracted from 
murine tissue of hepatocellular carcinoma could prevent further 
tumor invasion. When the pathway was investigated, results sug-
gested that the modulation of macrophage polarization by NCTD 
is somewhat mediated by miR-214 overexpression. TAMs from the 
same study showed downregulation of STAT3 phosphorylation, a 
mechanism that has been implicated in the shift of macrophage 
polarization from M2 to M1 in order to inhibit tumor growth 
and metastasis (93, 94). In fact, the STAT3 signaling pathway is 
now considered to be a crucial molecular target when it comes to 
pancreatic cancer. Arpin et al. have made that evident with their 
study using a 3D pancreatic ductal adenocarcinoma model and 
p-STAT3 inhibitors, which was effective even alongside CAFs. 
They suggest further study on STAT3 inhibition using the same 
model as an important tool to uncover alternative pathways to be 
explored in pancreatic cancer treatment (95).
One of the most traditional Chinese medicine, emodin is a 
natural anthraquinone obtained from Rheum palmatum L and 
other Chinese herbs (96). Interestingly, studies have confirmed 
that Emodin subdues breast cancer lung metastasis hindering 
the recruitment and polarization of macrophages toward M2 
phenotype in metastatic lung cancer. The substance had no 
influence over the primary tumor growth, however. Noted, 
TAMs have a particular subpopulation called metastasis-
associated macrophages, which can support metastatic growth 
(97–99). These cells are also a potential therapeutic target, since 
metastasis is generally non-responsive to current treatments. 
Another finding is that the regulation Emodin exhibited over 
macrophage polarization is through the p-STAT6 and C/EBPβ 
pathways (100).
The bioflavonoid Wogonin, isolated from Scutellaria radix, 
presents an antitumor properties based on its ability to modu-
late the tumor microenvironment. In previous studies, Wogonin 
showed activity through downregulation of MMP-9, which 
halted invasion of human breast carcinoma cells (101). Wogonin 
also prevented migration of A549 cells from human alveolar 
adenocarcinoma, which were used to study EMT, and, therefore, 
metastasis. The pathway involved in such response was once more 
via IL-6/STAT3, and Wogonin prevented the transition, which 
demonstrates its potential activity in metastasis (102).
Yet another plant extract shown to have modulation properties 
on macrophage polarization is isoliquiritigenin (ISL), a flavonoid 
from licorice. Is has been demonstrated that this substance acts 
in a chemo preventive manner via inhibition of M2 macrophage 
polarization, in a AOM/DSS-induced colitis-associated tumori-
genesis (both in vivo and in vitro). In this case, the modulation 
occurs through downregulation of the interaction among IL-6 
and PGE2. Furthermore, the results also proved a diminished 
COX-2 expression after stimulation with ISL and a decreased 
presence of M2 markers such as arginase-1 and CD206 in the 
lineage macrophages. Evidence showed that ISL inhibited M2 
polarization at least partially by the downregulation of the IL-6/
STAT3 pathway (103).
Another innovative research regarding modulation of macro-
phage polarization are cancer vaccines made of Listeria monocy-
togenes. The bacteria are attenuated by deletion of virulence factors, 
for instance, ActA and Internalin B (ΔactA/ΔinlB) (104). Studies 
have indicated that treatment with this attenuated strain targets 
mainly TAMs and reprograms them from M2 phenotype to M1, 
which activates antitumor responses (105). Results showed that 
the antitumor function of reprogrammed TAMs was due to nitric 
oxide production via Nos2 (105, 106). This antitumor response 
mediated by iNOS in repolarized macrophages is so strong that 
even in the absence of NK cells and CD8 T cells, viability is still 
maintained (105).
On the other hand, nanotechnology has also been developed 
to respond to several new-found cancer targets. Carbosilane den-
drimer 2G-03NN24 can cause polarization M2 to M1 polarization, 
decreasing the expression of several M2-related genes, which, in 
turn, increases the expression of M1 characteristics. These results 
were confirmed by functional assays, given the M1-oriented pro-
inflammatory and antitumor responses (107). The mechanism 
involved inhibits phosphorylation of STAT3, which boosts the 
capacity of macrophages to promote cytotoxic response and 
presentation of tumor antigens (107, 108). Furthermore, it has 
been demonstrated that a system composed of gold nanoparticles 
adapted with MUC-1 protein fragment was capable of promoting 
macrophage activation and M1 polarization, characterized by 
increased antigen presentation and M1-like cytokine expression 
(109). This mucin glycoprotein, MUC-1 or CD227, has been 
found to be a target for cytotoxic T lymphocytes, and possibly for 
immunotherapy, hence its use in a possible cancer vaccine (109, 
110). Of note, the impact of chemotherapy has been investigated 
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to ascertain what can influence recurrence of cancer. In a study 
of MCF-7 cells, after apoptosis induced by chemotherapy, there 
was activation of cancer stem-like cells (CD44+/CD24−) and 
upregulation of MUC-1 (111). Furthermore, it has been further 
demonstrated that, when macrophages were cocultured with 
MCF-7 cells suffering apoptosis, they secreted IL-6, activating 
STAT3 phosphorylation, and therefore performed a role on 
the activation of cancer stem cells and cancer promotion. Thus, 
there is accumulating evidence that blockage of the IL-6/STAT3 
pathway is an interesting new approach for metastatic cancer after 
chemotherapy (112).
Regarding resistance to chemotherapy, there is an increasing 
body of evidence suggesting the inherent role of the tumor micro-
environment in providing cancer cells with means to do so. In 
this matter, SFRP2 has been identified as Wnt pathway regulator 
secreted by fibroblasts and an active agonist of WNT16B, which 
intermediates cancer sensitivity to chemotherapy (113). It has 
been reported that SFRP2, secreted by stromal cells, triggers the 
canonical Wnt pathway and increases the WNT16B signaling, 
supporting resistance to chemotherapy. Furthermore, this effect 
can be abrogated by treatment with antibody as an adjuvant to 
the chemotherapy. Interestingly, this study considers WNT16B 
to be a novel biomarker to monitor the response of the tumor 
microenvironment to therapy (114).
Remarkably, it has increased the number of studies that 
emphasizes the crucial role of the crosstalk between the adipose 
tissue and cancer, as an important immunopharmacological tar-
get to tumor microenvironment, especially in breast cancer. Qin 
et al. explored that link by demonstrating the high fat diet cancer 
latency in C3(1)-Tag GEMMs, which is considered a coher-
ent model to study basal-like breast cancer, was postponed by 
weight loss when the mice were swapped to low fat diet instead. 
These interventions could effectively prevent atypical ductal 
hyperplasia and ductal carcinoma in situ to the points observed 
in healthy mice. In the same study, the weight loss caused 
decreased activity of several kinases, which, in turn, caused 
abrogation of the MAPK pathway, which is related to tumor 
proliferation (115). Another study set out to explore this con-
nection, studying breast cancer cells with overexpression of the 
HER-2 protein treated with trastuzumab, particularly regarding 
its ADCC mechanism, that is, the antibody-dependent cellular 
cytotoxicity. In this setting, it was demonstrated that not only 
adipocytes and preadipocytes prevented trastuzumab caused 
NK cell-tumor lysis in vitro but also adipose tissue abrogates the 
drug effect in vivo (116). Such effect can be expected once it has 
been reported that NK cell functions and characteristics can be 
swayed by the tumor microenvironment (117, 118). Interestingly, 
they not only display receptors for adipokines but also can have 
their cytotoxicity modulated by leptin and adipotectin (119, 
120). Therefore, the results of Duong et al. suggest that factors 
expressed by the adipose tissue are responsible for decreasing 
the sensitivity of HER-2 expressing breast cancer cells to trastu-
zumab. However, despite testing for several adipokines such as 
leptin, adiponectin, IL-6, and TNF-α, none were able to account 
for the ADCC inhibition observed (116).
The investigation of the crosstalk between adipose tissue and 
breast cancer led to interesting findings, using 3T3-L1 adipocytes 
and 4T1 breast cancer cells as a model and aspirin as the interven-
tion. It has been demonstrated that aspirin inhibited the prolif-
eration and migration of 4T1 cells and blocked communication 
between the two cell types in vitro, effect observed by the decrease 
in MCP-1 and PAI-1 expression in the cultured supernatant. 
Therefore, aspirin is expected to suppress the proliferation of 
breast cancer cells in an environment shared with obesity (121).
Given the influence the adipose tissue has on cancer promo-
tion, adipokines such as leptin are investigated to uncover their 
role on the matter. For instance, leptin and its receptor have been 
demonstrated to facilitate the interaction between cells from the 
tumor microenvironment, such as cancer-associated fibroblasts 
and adipocytes, and breast cancer stem cells (BCSCs). Both the 
pharmacological inhibition of leptin signaling and immunode-
pletion in the conditioned media used in the experiment both 
yielded the same result: decreased mammosphere formation 
in cells obtained from patients with metastatic breast cancer. 
Therefore, aiming for either leptin or signaling mediated by leptin 
receptor might eliminate BCSCs or even avert recurrences and 
metastasis completely in breast cancer patients (122). In a similar 
study considering the effect of leptin on TAMs and breast cancer 
cells, the adipokine has been shown to induce IL-18 expression 
on both, eventually leading the breast cancer cells to invasion and 
metastasis. In order to confirm the results, cells were co-incubated 
with IL-18 siRNA or IL-18BP-Fc chimeras and the effect of TAMs 
to promote migration and proliferation of breast cancer cells 
when stimulated by leptin was abrogated, thus proving the link 
between the process (123).
CONClUSiON
Adipocytes, macrophages, and tumor cells can orchestrate 
several signaling pathways that are crucial to the establishment 
of a microenvironment that can favor cancer progression. 
Immunomodulatory factors or free-fatty acids released by adipo-
cytes in lipolysis process can fuel tumor cells proliferation, trigger 
macrophages activation and polarization and control the fate 
of cancer development. Adipocytes and macrophages regulate 
themselves, generating an anti-inflammatory tumor microen-
vironment, preventing immune antitumor response cells from 
reaching the cancer site. Thus, abundance of white adipocytes and 
TAM with M2 profile can indicate poor prognosis for patients. 
Hence, the intimate signaling pathways triggered by those cells 
can function as a valuable pharmacological target to develop 
more efficient cancer treatments and should be further explored.
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